Zhongfu Technology: plans to acquire 87% of the equity of Junke Zhengyuan for 1 billion RMB. The target company is a leading CRO in innovative drug biomarker analysis.

Zhongfu Technology announced that its wholly-owned subsidiary Zhongfu Zhengyuan plans to acquire 87% of the equity of Junke Zhengyuan for 1 billion yuan. After the completion of the transaction, the company will hold 87% of the equity of Junke Zhengyuan after the completion of the CRO asset integration. Junke Zhengyuan will become a subsidiary of the company and be included in the company's consolidated financial statements. Junke Zhengyuan is a leading CRO in innovative drug bioanalysis with leading scientific capabilities and international advanced testing platforms. It has established a comprehensive bioanalysis technology cluster covering gene therapy and cell therapy, protein/peptide, monoclonal antibodies and multifunctional antibodies, ADC/PDC, nucleic acids, vaccines, small molecule drugs, etc., solving the bottleneck problems and key technical barriers in the research of various types of biotechnological drugs and small molecule drugs.